A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)

Trial Profile

A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 14 Jul 2018

At a glance

  • Drugs Ropotrectinib (Primary)
  • Indications Non-Hodgkin's lymphoma; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms TRIDENT-1
  • Sponsors TP Therapeutics
  • Most Recent Events

    • 05 Jun 2018 Results (data cut off: 2 Jan, 2018; n=65) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 04 Jun 2018 Interim results (n=72) from this trial presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, according to a TP Therapeutics media release.
    • 04 Jun 2018 Interim results (n=72) presented in a TP Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top